Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
Coming Soon – December 2019
Immune checkpoint inhibitors have revolutionized the treatment of multiple oncology indications, including non-small-cell lung cancer (NSCLC), malignant melanoma, and bladder cancer. As premium-priced immune checkpoint inhibitors gain label expansions for additional indications and approvals as part of combinatorial regimens, the high cost associated with these agents will continue to present significant challenges for payers. Developing a clear understanding of prescribing patterns and the reimbursement landscape for immune checkpoint inhibitors is critical to maximize commercial success.
GEOGRAPHY: United States
PRIMARY RESEARCH: Survey of 100 U.S. medical oncologists Survey of 30 U.S. managed care organization (MCO) pharmacy and medical directors (PDs/MDs)
KEY DRUGS COVERED: Keytruda, Opdivo, Yervoy, Tecentriq, Imfinzi, Bavencio
CONTENT HIGHLIGHTS Reimbursement and contracting Access and prescribing Special topics Opportunities and challenges for emerging therapies
Already a Client? Log in to access this report.
is a business insights analyst in the oncology team at Decision Resources Group. Ms. Mitchell previously worked as an analyst at financial PR firm, Tulchan Communications, where she provided news on the pharmaceutical sector from a commercial perspective. Prior to this, Ms. Mitchell was a project assistant within the consulting team at DRG-Abacus where she learnt about HEOR and market access. Ms. Mitchell obtained her Masters in Cancer Sciences from the University of Birmingham. The degree focused on the expression of immune checkpoints in DLBCL. She also holds a in Biomedical Science from the University of Reading.